Oncologic outcomes after minimally invasive segmentectomy or lobectomy in patients with hypermetabolic clinical stage IA1-2 non–small cell lung cancerCentral MessagePerspective by Alessandro Brunelli, MD, Joshil Lodhia, MD, Richard Milton, MD, Marco Nardini, MD, Kostas Papagiannopoulos, MD, Peter Tcherveniakov, MD, Demetrios Stefanou, MD, Elaine Teh, MD, Nilanjan Chaudhuri, MD

Get full text